Audit: QRS - Zeaxanthin for Health & Longevity
Audit conducted on 10/08/2026 23:34 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every span traced to ER source: protocol cells to ER Therapeutic Protocol (lines 332–338), time cells to Practical Considerations line 382, benefit/risk tiers to the ER tier headings, gates to Key Interactions & Contraindications (lines 294–314), monitoring rows to the ER biomarker table (lines 414–421). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER wording is carried verbatim: “Unresolved lung-cancer signal”, “Unknown safety above dietary amounts in pregnancy and lactation”, and marker 8’s “No established target; track change from the individual’s own baseline”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Tier assignments match the ER’s own tiers exactly; the pregnancy/lactation entry remains in the Contraindications gate, not downgraded to a Key Interaction. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No content from ER Benefit-Modifying Factors (lines 220–228) or Risk-Modifying Factors (lines 282–290) appears in any QRS section; each QRS section draws only from its mapped ER section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names, or brand names (Lutemax, FloraGLO, OPTISHARP, EZEyes) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present; the ER’s “Nutrition Research Centre Ireland” and “Moran Eye Center” attributions (line 334) were correctly dropped rather than carried over. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, non-promotional register matching the ER; the At-A-Glance mirrors the ER Conclusion’s own framing of dependable biomarker change versus unestablished clinical change. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and dose ranges throughout, paired with the reassuring safety framing (“Safety is reassuring at common amounts”) drawn from ER line 453. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as descriptions of documented approaches (“Standard eye-disease dose”, “Macular-pigment-loading approach”) rather than instructions issued to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive constructions; the Protocol panel names the trial-derived dose and the Monitoring table names the ER’s functional ranges without directing anyone to act. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “recommend”, “advise”, “should”, or “must” in the QRS body text. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document (verified across the full body text). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the ER’s own endpoint names (carotenodermia, nuclear cataract, photostress recovery time) and are necessary to name the finding; no avoidable jargon added. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every tier is a single semicolon-separated line, gate items are label-only, and all magnitudes, confidence intervals, and mechanisms from the ER are stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” constructions in any span or in the fixed footer text. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The Monitoring card assumes access to macular pigment optical density measurement, serum carotenoid panels, and hs-CRP — a self-quantifying, proactive audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The loading approach (10–20 mg total xanthophylls for six months, then step down) and the six-month/annual re-measurement cadence both presume sustained effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Eight quantified biomarkers with functional (not conventional laboratory) targets place the sheet well outside general-population material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance flags that slowed vision loss is seen “mainly in existing moderate disease”, preserving the ER’s distinction between the dependable biomarker gain and the narrower clinical signal. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the title uses “Health & Longevity” per the ER canonical_topic. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology throughout (“gastrointestinal discomfort”, “carotenodermia”, “hypersensitivity”); the plainer “digestive upset” in At-A-Glance is taken verbatim from ER Conclusion line 453 and is required by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed strings match [qrs_template] byte-for-byte: lines 445, 486, 528, 591, 619, 753 (headings), 561/571 (gates), the four <strong> tier labels in each of the Benefits and Risks cards, and lines 623–625 (column headers). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Programmatic set comparison against [qrs_template]: every template variable is present, with the repeated marker_#_* row expanded to marker_1_*–marker_8_* and qualitative_item_# expanded to qualitative_item_1–qualitative_item_5 as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Normalised structural diff of the <body> against [qrs_template] shows no change outside variable content and the intended row expansion; the <span website="evidence_review">, <span website="audit">, and <span website="full_review"> elements are untouched, and the <style> block is byte-identical. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped to the QRS is empty; every benefit tier, risk tier, gate, protocol, monitoring, and qualitative section in the ER carries content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels reproduce the ER bold labels exactly: “Standard eye-disease dose” (ER line 332), “Macular-pigment-loading approach” (line 334), “Best time of day” (line 338). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels; monitoring marker names match the ER table’s Biomarker column verbatim (ER lines 414–421), and time-to-effect labels are drawn from the ER’s own three time-to-effect clauses at line 382. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji code points occur anywhere in the file; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ Conflicted markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is condensed to the floor permitted by the other checklist items: all magnitudes, confidence intervals, mechanisms, and mitigations are stripped, each tier is one line, and gate items are label-only. No section was extended beyond its template structure. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the metadata comment opens immediately after <!doctype html> on line 1 and precedes the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3 and closing --- on line 13; the preamble text “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block is entirely inside an HTML comment and no metadata value is duplicated into any rendered element; the visible subline carries only the date and model, which are template-defined. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All nine values verified clean; only duration: "00:03" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: zeaxanthin_2026-0810-2145_Opus_ER.md, matching the ER’s own filename frontmatter field (ER line 17). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of [qrs_prompt]. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0810-2313, correctly formatted. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word carrying no version number or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version only, with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: zeaxanthin_2026-0810-2145_Opus_QRS.html, matching the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across lines 4–12, including the workflow-added git_user and git_issue fields; no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Zeaxanthin for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic (ER line 8) with the ampersand correctly entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Zeaxanthin for Health & Longevity, exactly the ER canonical_topic with & encoding. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/10/2026, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0810-2313. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching the qrs_creator_ai_fullname frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) is structurally identical to [qrs_template]; the ER’s “Also known as” line (ER line 30) was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Lines 434–437 compress all four load-bearing points of the ER Conclusion (lines 449–453): non-synthesis and retinal concentration, dependable dose-scaled pigment rise above a threshold, clinical benefit confined to existing moderate disease, and reassuring safety. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words (counted programmatically), within the 60-word ceiling. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct ER Conclusion passage: line 449 (cannot make it / eye concentrates it / threshold / scales), line 451 (mainly moderate existing disease), line 453 (safety reassuring, digestive upset the main complaint). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “macular pigment optical density” becomes “that pigment level”, “age-related macular degeneration” becomes “central vision loss”, and “gastrointestinal” becomes “digestive upset”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, participant counts, or p-values appear in the span. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No hazard ratios, confidence intervals, or unit changes; the ER’s “+0.04 units” and “hazard ratio 0.91” figures are absent. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All three items come from the “Populations who should avoid Zeaxanthin” list inside that ER section (ER lines 310–314). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Lines 564–566 reproduce all three ER avoid-populations with none omitted and none invented. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Three discrete <li> elements inside the stop_items span (lines 564–566). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing ER clauses stripped in all three: “the source material for most commercial zeaxanthin”, “given the absence of controlled safety data at any tested dose”, and “rather than for zeaxanthin itself”. No dash-trailing content remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | ”(Tagetes erecta)” preserved on item 1; the “at supplemental doses above dietary intake” qualifier and the “15 mg/day or more” threshold are both retained on items 2 and 3. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses in any avoid-population bullet. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does identify avoid-populations (lines 312–314), and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no empty-state HTML comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map one-to-one onto the eight interaction bullets at ER lines 294–308. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Lines 574–581 carry all eight ER interactions; none duplicates an avoid-population entry, and the beta-carotene interaction bullet (ER line 300) is correctly distinct from the smoker contraindication (ER line 314). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight discrete <li> elements inside the caution_items span (lines 574–581). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All Caution/Monitor/Additive tags, mechanism sentences, and “Mitigation:” clauses are stripped; the mechanistic parenthetical “(lipase inhibitor blocking fat digestion)” on Orlistat is correctly dropped as mechanistic rationale. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists and thresholds retained: “(cholestyramine, colestipol, colesevelam)”, “(15–30 mg)”, “(olestra-containing foods, psyllium with meals)”, “(25–80 mg elemental)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | No ranking notation appears inside parentheses in the ER’s interaction bullets; all parentheticals are already plain comma-separated lists or dose ranges. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER lists eight such interactions, and the section is populated accordingly. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no empty-state HTML comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action cells derive from the ER Therapeutic Protocol section (ER lines 332, 334, 338). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The trial-validated dose, the pigment-loading alternative, and dose timing are the three load-bearing decisions; the ER itself flags dosing without fat as “the most frequent cause of an apparent non-response” (ER line 388). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section lists eleven actionable aspects, well above three, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated: labels verbatim from the ER bold labels, values “2 mg zeaxanthin + 10 mg lutein daily” / “10–20 mg total xanthophylls daily” / “Largest fat-containing meal”, and subs drawn from ER lines 332, 334, and 338. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The three cells correspond exactly to the three clauses of the ER’s “Time to effect” bullet (ER line 382): macular pigment density, functional glare/contrast, and eye-disease progression. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order is macular pigment density (ER High tier), eye-disease progression (ER High tier), glare and contrast (ER Medium tier) — descending by the ER’s own benefit tiering. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so all three sets are used and none is left unfilled. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated from ER line 382: “4–8 weeks” / “Rises measurably, then plateaus near six months”, “Years” / “Effects only detectable across years”, “Tracks the pigment” / “Functional changes follow macular pigment density”. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER line 382), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven listed benefits map to the ER Expected Benefits headings (ER lines 150–216) with no additions from other ER sections. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 530–554), with tier membership matching the ER’s High/Medium/Low/Speculative groupings exactly. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; all Magnitude lines (+0.04 units, HR 0.91, RR 0.63, CRP −0.30 mg/L, HDL +4.06 mg/dL) and all mechanism and trial detail are stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any benefit tier; the ER’s ⚠️ Conflicted markers on two headings are likewise dropped per item 4.4. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven listed risks map to the ER Potential Risks & Side Effects headings (ER lines 236–278) with no content drawn from Risk-Modifying Factors. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 593–613), with tier membership matching the ER’s groupings exactly. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; the ER’s odds ratios (1.15, 1.82), dose thresholds, and mechanism sentences are all stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “Carotenodermia (Yellow-Orange Skin Discoloration)” (ER line 244) is correctly reduced to “Carotenodermia”; no parenthetical content remains in any risk tier. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table and cadence both derive from the ER Monitoring Protocol & Defining Success section (ER lines 408–421). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarker rows are present in order: macular pigment optical density, serum zeaxanthin, serum lutein, skin carotenoid score, high-sensitivity C-reactive protein, HDL cholesterol, photostress recovery time, contrast sensitivity. Targets and “Why” text match ER lines 414–421. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 744–747 reproduce the ER cadence from line 410: six-month then annual pigment and serum carotenoids, twelve-month lipids and inflammatory markers, dilated retinal examination every one to two years or annually with intermediate disease. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the “Qualitative markers worth tracking alongside the laboratory measures” list in the ER Monitoring Protocol & Defining Success section (ER lines 425–429). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are present verbatim and in ER order (lines 756–778); none omitted and none invented. |
Issues 10/08/2026 23:34
Pass rate 100.00%. No issues found.
Issues 10/08/2026 23:26
- 9.4 — Interaction classifier not stripped: Lines 579–580 carry an added parenthetical classifier — “Lutein, meso-zeaxanthin, and astaxanthin (additive)” and “Dietary fat and fish oil (additive, potentiating)” — which is elaboration rather than the key fact, and is inconsistent with the other six items where the ER’s “Caution”/”Monitor” classifiers were correctly dropped.
Fixes 10/08/2026 23:26
- 9.4 — Interaction classifier stripped: Removed the added parenthetical classifiers from the two Key Interactions items, so they now read “Lutein, meso-zeaxanthin, and astaxanthin” and “Dietary fat and fish oil”, consistent with the other six items.
Issues 10/08/2026 23:16
- 13.4 — Parenthetical preserved instead of stripped: In [risks_medium] (line 598) the ER sub-heading “Carotenodermia (Yellow-Orange Skin Discoloration)” is rendered as “Yellow-orange skin discoloration”, preserving the parenthetical content and dropping the term, the inverse of the required stripping.
Fixes 10/08/2026 23:16
- 13.4 — Parenthetical preserved instead of stripped: In [risks_medium] the entry “Yellow-orange skin discoloration” was replaced with “Carotenodermia”, stripping the ER sub-heading’s parenthetical gloss rather than the term outside it.